Home » Posts tagged with » Incyte
Lilly Covid drug trial : US pharma giant launches phase 3 trial of baricitinib

Lilly Covid drug trial : US pharma giant launches phase 3 trial of baricitinib

Lilly Covid drug trial : Eli Lilly and Company has enrolled the first patient in a phase 3 randomized, double-blind, placebo-controlled trial to assess the efficacy and safety of baricitinib in hospitalized adults with COVID-19. Baricitinib is an oral JAK1/JAK2 inhibitor, which was licensed by Lilly from Incyte. Marketed as OLUMIANT, baricitinib has approval in […]

Innovent Biologics begins parsaclisib phase 2 trial in follicular lymphoma

Innovent Biologics has dosed the first patient in a phase 2 trial of parsaclisib (IBI-376), a novel and selective PI3Kδ inhibitor in follicular lymphoma (FL). The goal of the study being held in China is to assess the efficacy and safety of parsaclisib in patients having recurrent or refractory follicular lymphoma or marginal zone lymphoma […]

Continue reading …
Incyte bags Pemazyre FDA approval for cholangiocarcinoma treatment

Pemazyre FDA approval : US biopharma company Incyte has bagged accelerated approval from the US Food and Drug Administration (FDA) for Pemazyre (pemigatinib) for the treatment of cholangiocarcinoma, a rare type of cancer occurring in the bile ducts. The approval is for adult patients having certain types of previously treated, advanced cholangiocarcinoma. According to the […]

Continue reading …
Incyte to launch ruxolitinib coronavirus clinical trial in US

Ruxolitinib coronavirus clinical trial : Incyte revealed that it is working with the US Food and Drug Administration (FDA) to launch the phase 3 RUXCOVID clinical trial to assess the efficacy and safety of ruxolitinib (Jakafi) plus standard-of-care (SoC) in patients with COVID-19 associated cytokine storm syndrome. The ruxolitinib plus standard-of-care will be compared to […]

Continue reading …
Incyte secures FDA priority review for pemigatinib in cholangiocarcinoma

Delaware-based pharma company Incyte has secured priority review for pemigatinib from the US Food and Drug Administration (FDA) for the treatment of locally advanced or metastatic cholangiocarcinoma. The priority review for pemigatinib is for the treatment of the condition in previously treated patients having FGFR2 fusions or rearrangements. Cholangiocarcinoma is a rare cancer that occurs […]

Continue reading …
Incyte, Innovent announce collaboration for three cancer drugs in China

US pharma company Incyte and Chinese biopharma company Innovent Biologics through their respective subsidiaries have entered into a deal worth up to $391.5 million for three investigational cancer drugs discovered and developed by the former. The three investigational cancer drugs – pemigatinib, a FGFR1/2/3 inhibitor, itacitinib, a JAK1 inhibitor and parsaclisib, a PI3Kδ inhibitor, are […]

Continue reading …